OTCMKTS:SKBI

Skystar Bio-Pharmaceutical Competitors

$0.0000

0.00 (0.00 %)

(As of 03/25/2019)

Add

Compare

Today's Range

$0.00

▼

$0.00

50-Day Range N/A

52-Week Range

$0.00

▼

$0.01

Volume25 shs

Average Volume1,983 shs

Market Capitalization$87.00

P/E RatioN/A

Dividend YieldN/A

Beta-175.12

Skystar Bio-Pharmaceutical (OTCMKTS:SKBI) Vs. ACUS, AFFY, ARYX, AHROQ, CBPI, and CDSG

Should you be buying SKBI stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Skystar Bio-Pharmaceutical, including Acusphere (ACUS), Affymax (AFFY), ARYx Therapeutics (ARYX), AtheroNova (AHROQ), China Botanic Pharmaceutical (CBPI), and China Dongsheng International (CDSG).

Skystar Bio-Pharmaceutical vs. Acusphere Stock

Acusphere (OTCMKTS:ACUS) and Skystar Bio-Pharmaceutical (OTCMKTS:SKBI) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Profitability

This table compares Acusphere and Skystar Bio-Pharmaceutical's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Acusphere	N/A	N/A	N/A
Skystar Bio-Pharmaceutical	N/A	N/A	N/A

Risk & Volatility

Acusphere has a beta of -0.25, suggesting that its share price is 125% less volatile than the S&P 500. Comparatively, Skystar Bio-Pharmaceutical has a beta of -175.12, suggesting that its share price is 17,612% less volatile than the S&P 500.

Valuation and Earnings

This table compares Acusphere and Skystar Bio-Pharmaceutical's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acusphere	N/A	N/A	N/A	N/A	N/A
Skystar Bio-Pharmaceutical	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a summary of current ratings for Acusphere and Skystar Bio-Pharmaceutical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acusphere	0	0	0	0	N/A
Skystar Bio-Pharmaceutical	0	0	0	0	N/A

Summary

Acusphere beats Skystar Bio-Pharmaceutical on 1 of the 1 factors compared between the two stocks.

Skystar Bio-Pharmaceutical vs. Affymax Stock

Affymax (OTCMKTS:AFFY) and Skystar Bio-Pharmaceutical (OTCMKTS:SKBI) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Profitability

This table compares Affymax and Skystar Bio-Pharmaceutical's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Affymax	N/A	N/A	N/A
Skystar Bio-Pharmaceutical	N/A	N/A	N/A

Risk & Volatility

Affymax has a beta of 2.77, suggesting that its share price is 177% more volatile than the S&P 500. Comparatively, Skystar Bio-Pharmaceutical has a beta of -175.12, suggesting that its share price is 17,612% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Affymax and Skystar Bio-Pharmaceutical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Affymax	0	0	0	0	N/A
Skystar Bio-Pharmaceutical	0	0	0	0	N/A

Valuation and Earnings

This table compares Affymax and Skystar Bio-Pharmaceutical's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Affymax	N/A	N/A	N/A	N/A	N/A
Skystar Bio-Pharmaceutical	N/A	N/A	N/A	N/A	N/A

Summary

Affymax beats Skystar Bio-Pharmaceutical on 1 of the 1 factors compared between the two stocks.

Skystar Bio-Pharmaceutical vs. ARYx Therapeutics Stock

ARYx Therapeutics (OTCMKTS:ARYX) and Skystar Bio-Pharmaceutical (OTCMKTS:SKBI) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, profitability and earnings.

Risk & Volatility

ARYx Therapeutics has a beta of -0.53, indicating that its share price is 153% less volatile than the S&P 500. Comparatively, Skystar Bio-Pharmaceutical has a beta of -175.12, indicating that its share price is 17,612% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for ARYx Therapeutics and Skystar Bio-Pharmaceutical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARYx Therapeutics	0	0	0	0	N/A
Skystar Bio-Pharmaceutical	0	0	0	0	N/A

Profitability

This table compares ARYx Therapeutics and Skystar Bio-Pharmaceutical's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ARYx Therapeutics	N/A	N/A	N/A
Skystar Bio-Pharmaceutical	N/A	N/A	N/A

Valuation & Earnings

This table compares ARYx Therapeutics and Skystar Bio-Pharmaceutical's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARYx Therapeutics	N/A	N/A	N/A	N/A	N/A
Skystar Bio-Pharmaceutical	N/A	N/A	N/A	N/A	N/A

Summary

ARYx Therapeutics beats Skystar Bio-Pharmaceutical on 1 of the 1 factors compared between the two stocks.

Skystar Bio-Pharmaceutical vs. AtheroNova Stock

Skystar Bio-Pharmaceutical (OTCMKTS:SKBI) and AtheroNova (OTCMKTS:AHROQ) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.

Valuation and Earnings

This table compares Skystar Bio-Pharmaceutical and AtheroNova's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skystar Bio-Pharmaceutical	N/A	N/A	N/A	N/A	N/A
AtheroNova	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Skystar Bio-Pharmaceutical and AtheroNova's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Skystar Bio-Pharmaceutical	N/A	N/A	N/A
AtheroNova	N/A	N/A	N/A

Volatility and Risk

Skystar Bio-Pharmaceutical has a beta of -175.12, indicating that its stock price is 17,612% less volatile than the S&P 500. Comparatively, AtheroNova has a beta of -8.71, indicating that its stock price is 971% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Skystar Bio-Pharmaceutical and AtheroNova, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skystar Bio-Pharmaceutical	0	0	0	0	N/A
AtheroNova	0	0	0	0	N/A

Summary

AtheroNova beats Skystar Bio-Pharmaceutical on 1 of the 1 factors compared between the two stocks.

Skystar Bio-Pharmaceutical vs. China Botanic Pharmaceutical Stock

China Botanic Pharmaceutical (OTCMKTS:CBPI) and Skystar Bio-Pharmaceutical (OTCMKTS:SKBI) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Earnings and Valuation

This table compares China Botanic Pharmaceutical and Skystar Bio-Pharmaceutical's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Botanic Pharmaceutical	N/A	N/A	N/A	N/A	N/A
Skystar Bio-Pharmaceutical	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares China Botanic Pharmaceutical and Skystar Bio-Pharmaceutical's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
China Botanic Pharmaceutical	N/A	N/A	N/A
Skystar Bio-Pharmaceutical	N/A	N/A	N/A

Volatility & Risk

China Botanic Pharmaceutical has a beta of 17.09, meaning that its stock price is 1,609% more volatile than the S&P 500. Comparatively, Skystar Bio-Pharmaceutical has a beta of -175.12, meaning that its stock price is 17,612% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for China Botanic Pharmaceutical and Skystar Bio-Pharmaceutical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Botanic Pharmaceutical	0	0	0	0	N/A
Skystar Bio-Pharmaceutical	0	0	0	0	N/A

Summary

China Botanic Pharmaceutical beats Skystar Bio-Pharmaceutical on 1 of the 1 factors compared between the two stocks.

Skystar Bio-Pharmaceutical vs. China Dongsheng International Stock

Skystar Bio-Pharmaceutical (OTCMKTS:SKBI) and China Dongsheng International (OTCMKTS:CDSG) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Profitability

This table compares Skystar Bio-Pharmaceutical and China Dongsheng International's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Skystar Bio-Pharmaceutical	N/A	N/A	N/A
China Dongsheng International	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings for Skystar Bio-Pharmaceutical and China Dongsheng International, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skystar Bio-Pharmaceutical	0	0	0	0	N/A
China Dongsheng International	0	0	0	0	N/A

Volatility & Risk

Skystar Bio-Pharmaceutical has a beta of -175.12, meaning that its stock price is 17,612% less volatile than the S&P 500. Comparatively, China Dongsheng International has a beta of 13.38, meaning that its stock price is 1,238% more volatile than the S&P 500.

Valuation & Earnings

This table compares Skystar Bio-Pharmaceutical and China Dongsheng International's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skystar Bio-Pharmaceutical	N/A	N/A	N/A	N/A	N/A
China Dongsheng International	N/A	N/A	N/A	N/A	N/A

Summary

China Dongsheng International beats Skystar Bio-Pharmaceutical on 1 of the 1 factors compared between the two stocks.